Results 81 to 90 of about 13,727 (197)

Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure

open access: yesRevista Portuguesa de Cardiologia, 2019
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA)
J. Silva-Cardoso   +10 more
doaj   +1 more source

Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction

open access: yes, 2016
Importance  The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril.
Chan, Wing W.   +9 more
core   +1 more source

Sacubitril/valsartan: um importante avanço no puzzle terapêutico da insuficiência cardíaca

open access: yesRevista Portuguesa de Cardiologia, 2017
Resumo: O sacubitril/valsartan (LCZ696) é um complexo supramolecular de sal de sódio do pró‐fármaco sacubitril, inibidor da neprilisina, e do valsartan, um antagonista dos recetores da angiotensina (ARB), administrado por via oral, recentemente aprovado ...
Pedro Marques da Silva, Carlos Aguiar
doaj   +1 more source

Divergent Electrophysiologic Effects of Sacubitril in Digitalis- and Pinacidil-Related Shortened Repolarization: Experimental Evidence for Harmful Effects of Digitalis Glycosides

open access: yesPharmaceutics
Background: Recent studies reported an abbreviation of cardiac repolarization induced by sacubitril. Thus, the purpose of this study was to evaluate the electrophysiologic effects of sacubitril in the presence of drugs that shorten the QT interval ...
Christian Ellermann   +7 more
doaj   +1 more source

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

Improving Postdischarge Outcomes in Acute Heart Failure [PDF]

open access: yes, 2018
The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P.   +8 more
core   +1 more source

The Effects of Angiotensin Receptor Neprilysin Inhibitor on Endoplasmic Reticulum Stress in Doxorubicin‐Mediated Cardiomyopathy‐Associated Heart Failure Model in Rats

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan   +3 more
wiley   +1 more source

Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]

open access: yes, 2019
The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio   +3 more
core   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

open access: yesMed Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang   +22 more
wiley   +1 more source

Declining risk of sudden death in heart failure [PDF]

open access: yes, 2017
No abstract ...
Jhund, Pardeep S.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy